Atlas Trials

Durvalumab(MEDI4736)/Tremelimumab in Combination With Gemcitabine/Cisplatin in Chemotherapy-naïve Biliary Tract Cancer

Clinical trial NCT03046862 · UNKNOWN

Trial details

NCT number
NCT03046862
Sponsor
Seoul National University Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Biliary Tract Neoplasms
Start date
2017-02-25
Primary completion
2020-05-30
Enrollment
31

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.